FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer ; volume:8 ; number:1 ; day:17 ; month:9 ; year:2024 ; pages:1-7 ; date:12.2024
npj precision oncology ; 8, Heft 1 (17.9.2024), 1-7, 12.2024
- Urheber
-
Stein, Leah
Murugesan, Karthikeyan
Reeser, Julie W.
Risch, Zachary
Wing, Michele R.
Paruchuri, Anoosha
Samorodnitsky, Eric
Hoskins, Emily L.
Dao, Thuy
Smith, Amy
Le, Dat
Babcook, Melissa A.
Chang, Yi Seok
Avenarius, Matthew R.
Imam, Muhammad
Freud, Aharon G.
Roychowdhury, Sameek
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41698-024-00683-x
- URN
-
urn:nbn:de:101:1-2411302110599.900068902901
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Stein, Leah
- Murugesan, Karthikeyan
- Reeser, Julie W.
- Risch, Zachary
- Wing, Michele R.
- Paruchuri, Anoosha
- Samorodnitsky, Eric
- Hoskins, Emily L.
- Dao, Thuy
- Smith, Amy
- Le, Dat
- Babcook, Melissa A.
- Chang, Yi Seok
- Avenarius, Matthew R.
- Imam, Muhammad
- Freud, Aharon G.
- Roychowdhury, Sameek
- SpringerLink (Online service)
Ähnliche Objekte (12)
KANK1-NTRK3 fusions define a subset of BRAF mutation negative renal metanephric adenomas
Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors
Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors
Discovery of clinically relevant fusions in pediatric cancer
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
Prevalence of clinically actionable disease variants in exceptionally long-lived families
High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma
Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma
Priority index for critical Covid-19 identifies clinically actionable targets and drugs
Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
Differentiation‐related epigenomic changes define clinically distinct keratinocyte cancer subclasses
KANK1-NTRK3 fusions define a subset of BRAF mutation negative renal metanephric adenomas
Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors
Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors
Discovery of clinically relevant fusions in pediatric cancer
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
Prevalence of clinically actionable disease variants in exceptionally long-lived families
High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma
Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma
Priority index for critical Covid-19 identifies clinically actionable targets and drugs
Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
Differentiation‐related epigenomic changes define clinically distinct keratinocyte cancer subclasses
KANK1-NTRK3 fusions define a subset of BRAF mutation negative renal metanephric adenomas
Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors
Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors
Discovery of clinically relevant fusions in pediatric cancer
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
Prevalence of clinically actionable disease variants in exceptionally long-lived families
High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma
Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma
Priority index for critical Covid-19 identifies clinically actionable targets and drugs
Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers